Pharma, Food, Flatbed, and Automotive. The Four Re-shoring Freight Lanes Small Carriers Can Actually Win — and the One They Should Stop Chasing.

The Gap Between the Headline and the Freight The White House published a press release on April 22, 2026, titled “Trump Effect: American Manufacturing Is Roaring Back as Factory Activity Hits Four-Year High.” The ISM Manufacturing PMI did reach 52. 7 in March 2026 — a multi-year high that signals genuine expansion in domestic manufacturing activity.

The administration counts over 100 companies that have pledged to reshore or expand domestic production. Here is what those numbers do not tell you. IoT Analytics, which tracks manufacturing construction data from the U. S.

Census Bureau’s Value of Construction Put in Place survey, published an analysis concluding that it is too early to characterize what is happening as a reshoring boom.

Manufacturing construction spending excluding computer and electronic products — which is dominated by semiconductor fabs that generate relatively little trucking freight per dollar invested — rose approximately 5. 6% between February 2025 and March 2026 in nominal terms. Adjusted for the 3.

3% annual inflation rate as of March 2026, real growth in manufacturing construction was approximately 2. 3%. Manufacturing employment has declined 1% since the widespread tariffs took effect, with only a slight uptick in the most recent data. Meanwhile, the Kearney Reshoring Index, which measures year-over-year change in the U. S.

manufacturing import ratio, shows that while 2025 was modestly better than 2024 for domestic production share, the U. S. remained well below the levels that would indicate a structural reshoring trend.

And a December 2025 Institute for Supply Management survey of companies found that 64% had no plans to reshore operations — compared to only 36% planning to or actively doing so. The freight reality that a carrier needs to understand is this: there is no across-the-board manufacturing boom generating a rising tide of new domestic freight.

What there is — and what is directly actionable right now — is a specific set of industry sectors where domestic production investment is real, already underway, and generating truck freight that is not yet fully locked into routing guides.

Those sectors are pharma, food and beverage, flatbed-adjacent construction materials, and regional automotive supply chains. Each one moves differently, requires different positioning, and rewards different kinds of carrier preparation.

Pharmaceutical: The Sector With the Most Freight Already Moving Pharmaceutical manufacturing is the sector where reshoring is most concretely real and where the freight implications for regional carriers are most immediate.

Eli Lilly announced a $27 billion domestic manufacturing investment plan that includes facilities in Indiana, North Carolina, Wisconsin, and Alabama. The Alabama facility broke ground in 2026 as part of that plan and represents one of the largest pharmaceutical manufacturing investments in that state’s history.

Merck has an active domestic vaccine and biologics manufacturing program. Johnson & Johnson announced a $55 billion domestic manufacturing pledge in 2025, with production expected to ramp across a five-to-seven-year timeline. The freight profile of a pharmaceutical manufacturing facility is specific and worth understanding precisely.

Large pharmaceutical plants do not generate enormous volumes of outbound truckload freight the way a consumer goods distribution center does.

What they generate is a consistent, high-frequency movement of regulated inputs, controlled substances, packaging components, and finished product — much of it temperature-sensitive, much of it requiring chain-of-custody documentation, and much of it moving on short regional lanes between facilities, distribution points, and specialty logistics hubs.

This is not dry van spot freight. This is relationship-dependent, compliance-intensive, high-value-per-mile freight.

For a carrier positioned to move pharmaceutical freight — which requires understanding temperature requirements, chain-of-custody documentation, facility access protocols, and the compliance infrastructure that a pharmaceutical shipper demands before awarding a lane — the barrier to entry is real. But the barrier functions as a moat, not just an obstacle.

Every compliance requirement that a small carrier meets is one that a less-prepared competitor cannot match. The carriers who invested in the carrier packet, safety record, and direct shipper outreach process described in previous articles on this platform are the ones who can walk into a pharmaceutical logistics conversation and present themselves credibly.

The ones who have not done that work cannot get in the door. The practical first step is geographic. Identify which pharmaceutical manufacturing facilities — including existing ones and announced expansions — operate within a 300-mile radius of your home base. The Reshoring Initiative’s database at reshorenow.

org tracks announced domestic manufacturing projects by state and industry. Cross-reference that aga